
|Articles|November 21, 2014
Convection-Enhanced Delivery of Nanoliposomal Irinotecan for Recurrent Glioblastoma or High-Grade Glioma
Author(s)Nicholas Butowski, MD
Nicholas Butowski, MD, discusses a phase I study of convection-enhanced delivery of nanoliposomal irinotecan (MM-398) for the treatment of recurrent glioblastoma or recurrent high-grade glioma.
Advertisement
Clinical Pearls
Nicholas Butowski, MD, associate professor, University of California, San Francisco, neuro-oncologist, UCSF Medical Center, discusses a phase I study of convection-enhanced delivery of nanoliposomal irinotecan (MM-398) for the treatment of recurrent glioblastoma or recurrent high-grade glioma.
- 1-3 catheters co-deliver liposomal-irinotecan and gadolinium into a patient’s tumor.
- Gadolinium is used so that imaging can be done in real-time.
- This process is unique because it bypasses systemic toxicity and ensures that the drug is administered properly.
<<<
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Breast Cancer Test Using Proteomic Profiling and AI Demonstrates High Performance
5










































